Last reviewed · How we verify
Omitted Doxorubicin (omitted-doxorubicin)
At a glance
| Generic name | omitted-doxorubicin |
|---|---|
| Sponsor | Pfizer Inc. |
| Phase | Phase 3 |
Approved indications
Common side effects
Key clinical trials
- A Treatment Study Protocol for Participants 0-45 Years With Acute Lymphoblastic Leukaemia (PHASE3)
- Therapeutic Trial for Patients With Ewing Sarcoma Family of Tumor and Desmoplastic Small Round Cell Tumors (PHASE2)
- Pediatric Classical Hodgkin Lymphoma Consortium Study: cHOD17 (PHASE2)
- Feasibility of Total Neoadjuvant Treatment With HYPErthermia in Patients With High-risk Extremity and Trunk Soft Tissue Sarcoma (TNT-HYPE) (PHASE2)
- Mosunetuzumab-Lenalidomide Versus Investigator Choices in Patients With Relapsed or Refractory Marginal Zone Lymphoma (PHASE3)
- A Study of Glofitamab-based Treatment in People With Diffuse Large B-cell Lymphoma (PHASE2)
- Efficacy and Safety of IMAB362 in Combination With the EOX Regimen for CLDN18.2-positive Gastric Cancer (PHASE2)
- GAMEC-II, Risk-adapted Protocol for Relapsed Germ Cell Tumours (GCT) (PHASE2)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- Omitted Doxorubicin CI brief — competitive landscape report
- Omitted Doxorubicin updates RSS · CI watch RSS
- Pfizer Inc. portfolio CI